A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease

Summary

Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early in CKD, and is undertreated. Vitamin D may have important effects on factors that drive proteinuria and renal disease progression in patients with proteinuric renal diseases. Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.

Timeline

Start

2006-07

Primary completion

2008-01

Completion

2008-01

Outcome

Met primary endpoint

Stopped: “Investigator left the Institution.”

paper Changes in protein excretion from baseline to last evaluation were +2.9% for controls and -17.6% for the paricalcitol group (P = 0.04). PMID 19596163 ↗

Publications

• Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paricalcitol	Other / unclassified	1 ug	Oral

Indications